Intellia Therapeutics Inc.

03/04/2022 | Press release | Distributed by Public on 03/04/2022 09:09

Intellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Decision Relating to CRISPR/Cas9 Genome Editing Technology in Eukaryotic Cells